$Veracyte (VCYT.US)$
Revolutionary Blood Test Detects Cancer Return 3 Months Earlier Than Imaging

$Veracyte (VCYT.US)$
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical Studies - New Product Coming

Artisan Partners Limited Partnership 5,402,362 shares, 8.5%
$Veracyte (VCYT.US)$
has options
nfa

$Veracyte (VCYT.US)$
The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages:
First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...

$Veracyte (VCYT.US)$
Revolutionary Cancer Test Results: Veracyte's Decipher Unlocks Personalized Treatment Success

$Veracyte (VCYT.US)$
Veracyte's Decipher Tests Dominate ASCO GU 2025 with Groundbreaking Cancer Detection Results

$Veracyte (VCYT.US)$
Clinical Study: Revolutionary Bladder Cancer Test Predicts Disease Progression with 33% Higher Accuracy

Cathie Wood and Ark Invest's trade activity from today 9/10
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...